Glaukos is positioned for strong growth with the commercialization of iDose TR, a novel drug therapy for glaucoma, and the introduction of the iStent infinite. Despite competition in the MIGS market and potential reimbursement challenges, the company has a robust pipeline and a strong relationship with payors. The recent discontinuation of Photrexa may provide headwinds, but new product launches and continued pipeline progress could drive significant value for investors.
Bears say
Glaukos is facing potential challenges with key products, due to lower growth expectations for iDose, LCD restrictions, and slow kit acquisition for Epioxa. These factors could impact revenue and profitability, leading to potential downside to the current valuation and price target for the company.
Glaukos (GKOS) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Glaukos (GKOS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Glaukos (GKOS) a Strong Buy based on their latest research and market trends.
According to 10 analysts, Glaukos (GKOS) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $145, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $145, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Glaukos (GKOS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.